Keywords: ALCL, anaplastic large cell lymphoma; ALK, anaplastic lymphoma kinase; BV, brentuximab vedotin; Bcl-2, B-cell lymphoma 2; CLA, cutaneous lymphocyte antigen; EMA, epithelial membrane antigen; FDA, US Food and Drug Administration; PC-ALCL, primary cutaneous anaplastic large cell lymphoma.